AusBiotech 2026: Company Directory

Argenica Therapeutics (ASX: AGN) in an Australian based clinical stage neurology company, developing novel therapies to treat acute brain injury. The Company's lead clinical program is in moderate to severe acute ischaemic stroke, with planning currently underway for a global Phase 2b/3 trial to assess the efficacy of its peptide drug xaranetide. The Company is also progressing the clinical development of xaranetide in traumatic brain injury. 

Learn more on the Argenica Therapeutics  website.

Atherid Therapeutics Pty Ltd is a biotech company developing ATH01, a first-in-class biologic designed to remove cholesterol and lipids directly from the arterial wall. It targets established plaque rather than reducing circulating cholesterol.

Lipid-lowering therapies can modestly shrink plaque, but only indirectly, by lowering circulating LDL over months to years. ATH01 is a recombinant protein conjugated to a plaque-targeting small molecule that guides the protein to atherosclerotic plaque in diseased arteries.

Our lead indications are homozygous familial hypercholesterolemia, a rare disease with severe unmet need, and peripheral artery disease in people with diabetes. Atherid is completing final preclinical studies and scaling up manufacturing with its CDMO. Next, we will conduct non-human primate toxicology and safety studies to support a first-in-human trial in Australia, within a development program built to meet FDA and EMA requirements.

Learn more on the Atherid Therapeutics website.

Learn more on the BioCina website.

ChemCentre is Western Australia’s leading provider of specialised chemical and forensic science services. 

We aim to provide an outstanding service to all our clients, stakeholders and the wider community, for a safer and more prosperous Western Australia. From advanced chemical testing to research collaboration, method development, and regulatory support, our team delivers the data and insights needed to accelerate innovation and reduce risk. 

Visit our team at AusBiotech to discover how we support research, development, and commercialisation through world-class analytical capabilities and practical data-driven solutions. 

Learn more on the ChemCentre website.

The Department of Energy and Economic Diversification drives Western Australia’s energy transition and long-term economic growth for a stronger, more diverse WA economy. We promote the State nationally and internationally to increase trade and attract investment. Our department fosters our already leading science, research and innovation sectors to build a technologically advanced and prosperous future for all Western Australians.

Western Australia is fast becoming a global hub for health and medical life sciences, supported by its proximity to the growing ASEAN market and strong health leadership. Our health and medical life sciences industry has more than doubled in the five years from 2017 to 2022. Western Australia's collaborative and vibrant ecosystem includes more than 100 medtech, digital health and biotech companies, 21 research institutes and foundations, 5 universities and 6 tertiary hospitals.

We operate an extensive network of international offices across the ASEAN region, China, India-Gulf, North-East Asia, United Kingdom/Europe and Americas regions.

Learn more on the Invest and Trade WA website.

Inspiring has developed and is commercialising its world first, novel and globally patented Universal Spacer System (USS) medical device, a platform device designed to improve delivery efficiency, dose consistency and safety across inhaled medicines. 

Current devices are inefficient, inconsistent and wasteful, with the USS device addressing all of these key issues – increasing drug delivery by up to 5x, consistently across various breathing patterns, and significantly reduces fugitive aerosol that reduces cross contamination and spread of infection risk. In addition to serving the asthma, COPD, CF markets, the Company aims to capitalize on the significant growth of high value inhaled biologics, peptides, vaccines, gene therapy and the like – which opens up global pharmaceutical partnerships to complement the traditional retail model. 

Inspiring is currently preparing for its agreed US FDA (and elsewhere) regulatory submission, including the required testing, and will be seeking strategic partners and distributors in the inhaled therapy space to commercialise this significant global opportunity with.

Learn more on the Inspiring website.

Linear Clinical Research is a not-for-profit clinical trial organisation based in Perth, Western Australia. We support biotechnology and pharmaceutical companies developing new therapies, with a focus on first-in-human and complex early-phase studies across healthy volunteers and patient populations.

Our experienced medical and operational teams engage early to understand your program, assess feasibility and develop an evidence-based recruitment plan. Once your study is awarded, your accountable Project Manager coordinates delivery from mobilisation through to closure, giving you continuity, clear communication and focused support throughout the study.

Our recruitment capability combines a community of more than 135,000 registered participants with evidence-based forecasting and dedicated participant support. As a successful not-for-profit organisation, we reinvest in the people, systems and capabilities behind study delivery.

Learn more on the Linear Clinical Research website. 

Learn more on the Neuroscientific website. 

OncoRes Medical is a Western Australian medical technology company. Our investigational ELORA® probe is designed to give surgeons real-time assessment of the tissue inside the surgical cavity, using micro-scale imaging. ELORA is currently being evaluated in clinical investigation. Its clinical performance has not yet been established. We welcome conversations with researchers, clinicians and potential collaborators.

Learn more on the OncoRes Medical website. 

At Orthocell we help surgeons maximise the healing potential of the human body. Since 2010 we have applied our deep understanding of regenerative medicine to create products that help surgeons improve the quality of life of their patients. Our regenerative medicine solutions span treatments for bones, nerves and tendons, treating more than 75,000 patients worldwide so far. Our product range supports surgeons to provide the best care for their patients. Remplir™ is a collagen nerve wrap that protects nerves and supports healing. Striate+™ is used for dental guided bone and tissue regeneration. OrthoATI™ and OrthoACI™ are cell therapies for tendon and cartilage repair respectively. 

By advancing the science of tissue repair and regeneration, we strive to help patients recover what injury or disease has taken from them by improving mobility, function and performance. 

Learn more on the Orthocell website. 

Perron Institute for Neurological and Translational Science is Western Australia’s longest established medical research institute, undertaking cutting-edge research in the neurological sciences. Our research laboratories are co-located with statewide specialist neurology clinics, and we connect clinicians, researchers, and communities to develop new methods of diagnosis, treatment, and prevention, improving the lives of people with neurological conditions.

Learn more on the Perron Institute website.

Resonance Health is an Australian MedTech company specialising in non-invasive medical imaging analysis and clinical trial imaging services. Its regulated imaging technologies have regulatory clearances and registrations across key markets, including the FDA, CE Mark and Australian ARTG, with UK registration supported through the applicable CE Mark extension.

Core products include FerriScan®, an MRI-based solution for quantitative liver iron concentration (LIC) measurement and widely regarded as the global gold standard for LIC quantification, and HepaFatScan®, an MRI-based solution for assessing liver fat using quantitative measures including proton density fat fraction (PDFF) and volumetric liver fat fraction (VLFF).

Resonance Health also provides quantitative imaging analysis and imaging CRO services for multinational and multicentre clinical trials. Its services include imaging charter development, site setup and qualification, secure image transfer, centralised analysis, clinical reporting and project management, supporting standardised imaging endpoints across multiple trial sites.

Resonance Health’s imaging technologies have been incorporated into clinical research programmes as primary and secondary imaging endpoints, supporting pharmaceutical and biotechnology companies in the development of new therapies.

Learn more on the Resonance Health website. 

Founded by Professor Rakesh Veedu, who is a recognised expert in nucleic-acid chemistry, oligonucleotide therapeutics, and drug delivery. Syngenis was established in 2020 to build long-term, domestic capacity in DNA and RNA technologies at a time when Australia relied heavily on offshore suppliers for advanced nucleic-acid manufacturing. Professor Veedu has spent more than two decades working in the DNA and RNA sciences, with a strong focus on translating laboratory research into practical diagnostic and therapeutic applications. His work spans nucleic-acid design, chemical modification and delivery systems, and he has led multiple research programs aimed at moving nucleic-acid technologies closer to real-world medical use.

From its inception, Syngenis was shaped by the involvement of Professor Marvin Caruthers, the inventor of phosphoramidite chemistry, which underpins modern synthetic DNA and RNA manufacturing worldwide. Professor Caruthers served as an inaugural Director, providing foundational guidance on the chemistry, manufacturing principles, and long-term strategic direction of the business.

Learn more on the SynGenis website. 

Our mission is to improve the health, development and lives of children and young people through excellence in research.

At The Kids, our dedicated team of researchers, clinicians, and students work together with global collaborators to improve the health and wellbeing of children and families affected by some of the most challenging and widespread health issues. Our world-leading researchers have identified early intervention programs for children with developmental delays, found that folic acid in a mother’s diet before and during pregnancy helps prevent neural tube defects, played a pivotal role in the introduction of world-first respiratory syncytial virus immunisation that has saved many lives and prevented hundreds of babies being hospitalised, and identified that a new immunotherapy in combination with standard-of-care chemotherapy improved survival rates for babies with leukaemia.

Learn more on the The Kids Research Institute website. 

The University of Western Australia (UWA) is a globally recognised research intensive university, bringing together world leading expertise, cutting-edge research infrastructure and deep industry partnerships. From local opportunities to global challenges, our researchers work with industry to solve complex challenges, develop new ideas and translate research into real-world impact.

Whether you’re looking for specialist expertise, a research collaborator, access to world-class facilities, or opportunities to develop and commercialise new technologies, we’ll help connect you with the right people and pathways at UWA.

Bring us your R&D challenge and discover what's possible with research at UWA.

Learn more on the UWA website.

TrialsWest is a leading Australian clinical trial site management organisation dedicated to the efficient and high-quality delivery of Phase Ib–IV clinical trials across a wide range of therapeutic areas. Established to meet the growing demand for reliable, patient-focused clinical research in Western Australia, TrialsWest provides end-to-end site management services that uphold the highest standards of clinical and operational excellence.

Our experienced Investigators and Research Coordinators work collaboratively to ensure every trial is conducted with precision, transparency, and in full compliance with Good Clinical Practice (GCP) and all applicable regulatory frameworks.

With a growing network of purpose-built clinics strategically located across Western Australia, TrialsWest combines local expertise with international quality standards.

At the core of our operations is a commitment to participant safety, data accuracy, and continuous improvement. TrialsWest enables its partners to generate dependable clinical evidence that accelerates the development of new treatments and improves health outcomes for patients worldwide.

Through our leadership and collaborative partnerships, TrialsWest plays a pivotal role in bringing world-class clinical research opportunities to Western Australia—strengthening the region’s position as a key contributor to global medical advancement. 

Learn more on the TrialsWest website. 

WALSIH is a partnership between AUScelerate (Australia’s life sciences innovation accelerator), the Western Australian Government and the University of Western Australia, established in 2018 to support the growth of WA’s medtech, biotech, pharmaceutical and digital health sector.

We focus on supporting those in WA creating, developing and commercialising novel medical products.  Through our ‘concierge service’ we help advise, inform and guide start-ups, scale-ups and innovators.  We provide targeted training programs to upskill and transform the local workforce and host events and partnerships to connect across the WA ecosystem.  WALISH has relationships (bio-bridges) to connect WA to the world, and the world to WA. 

Health start-ups are born focused on a growing global market. At WALSIH, our objective is to create a vibrant and connected WA ecosystem that nurtures these global ambitions to build a thriving local industry – delivering profit and impact on patients.

Learn more on the WA Life Sciences Innovation Hub website.